SEMAGLUTIDE 5mg 5x1mg ZPHC
Semaglutide — agonist receptors GPP-1
Description
Semaglutide predstavlyaet soboy analog GPP-1, imeyushchiy 94% gomologichnosti with chelovecheskim GPP-1. Semaglutide deystvuet as agonist receptors GPP-1, which selektivno svyazyvaetsya with retseptorom GPP-1, yavlyayushchimsya mishenyu for nativnogo GPP-1, and aktiviruet ego. GPP-1 is fiziologicheskim gormonom, which exerts mnozhestvennoe action in regulyatsiyu concentration glucose, oposredovannoe retseptorami GPP-1. Osnovnym mekhanizmom action, obuslovlivayushchim dlitelnyy T1/2 semaglutida, is svyazyvanie with albuminom, which privodit k reduction pochechnogo klirensa and zashchite from metabolicheskoy degradatsii. Krome that, ferment DPP-4 stabiliziruet semaglutid protiv razrusheniya. Semaglutide reduces level glucose in krovi thanks to mekhanizmu, in kotorom in stimulates secretion insulin and reduces secretion glucagon, prichem oba protsessa zavisyat from level glucose. Takim obrazom, in vysokom urovne glucose in krovi stimuliruetsya secretion insulin and podavlyaetsya secretion glucagon. Mekhanizm reduction level glucose in krovi also vklyuchaet neznachitelnuyu retention gastric emptying in ranney postprandialnoy faze.
Specifications
Semaglutide — chelovecheskiy agonist receptors GPP-1 (ili analog GPP-1). Peptidnuyu osnovu poluchayut putem fermentatsii drozhzhey. Osnovnym mekhanizmom action semaglutida is svyazyvanie with albuminom, chemu supports modifikatsiya lizina in position 26 gidrofilnym speyserom and zhirnoy dikislotoy C18. Krome that, semaglutid modifitsirovan in position 8 for obespecheniya stabilizatsii protiv degradatsii fermentom DPP-4. Neznachitelnaya modifikatsiya byla provedena in position 34, chtoby obespechit prisoedinenie only odnoy zhirnoy dikisloty. Molekulyarnaya massa is 4113,58 g/mol.
Composition / properties
Tip:Inektsionnye products
Manufacturer:ZPHC
Active ingredient: SEMAGLUTIDE
Fasovka: 1vial 5mg
Product FAQ
Usage guide
1-4 nedelya → 0.25 mg • 5-8 nedelya → 0.5 mg • in khoroshey perenosimosti uvelichit dose do 1 mg in per week. --- [Q] monitoring quality farmatsevticheskoy produktsii
purity ≥ 99 %, endotoxin <0,03 ES / mg; in kazhdoy korobke nanesen skretch-kod authenticity. --- [Q] Uroven glucose fasting and post-meal
Semaglutide reduces concentration glucose fasting and post-meal. U patients with diabetom type 2 treatment with semaglutide in doze 1 mg led k reduction level glucose in plane absolyutnogo changes otnositelno iskhodnogo level and otnositelnogo reduction compared with placebo in 29 mg/dl (22%) for level glucose fasting, 74 mg/dl (36%) for level glucose every 2 ch post-meal and 30 mg/dl (22%) for average 24-24-hour concentration glucose. --- [Q] Secretion insulin
U patients with diabetom type 2, poluchayushchikh semaglutid, secretion insulin as in first, tak and vtoruyu fazu increases compared with patsientami, poluchayushchimi placebo. --- [Q] Secretion glucagon
Semaglutide reduces concentration glucagon fasting and post-meal. U patients with diabetom type 2 treatment with semaglutide led k sleduyushchemu otnositelnomu reduction level glucagon compared with placebo: level glucagon fasting (8%), otveta glucagon post-meal (14–15%) and average 24-24-hour concentration glucagon (12%). --- [Q] Oporozhnenie zheludka
Semaglutide vyzyvaet retention rannego gastric emptying post-meal, for those samym reducing skorost postupleniya glucose in bloodstream post-meal.
Reviews
Leave a review
Similar products
Similar products from this category. This is a separate block and not the same item from another warehouse.
You may also like
